Program
ulonivirine
Also written as “Ulonivirine”, “ULO” and “MK-8507”.
Its studies are mostly in Infections · Hepatic Insufficiency, led by Merck.
Furthest: phase 3, since Dec 1, 202510 company-led studies, 3 open or runningNext primary completion: Jun 29, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 103 open or running | phase 3since Dec 1, 2025 | Jun 24, 2014 | Jun 29, 2027phase 1 · NCT05093972 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 24, 2014First study: phase 1 study in HIV-1 InfectionFirst studyNCT02174159 · 18 enrolled
- Sep 21, 2020Phase 2 study in HIV-1 InfectionNCT04564547 · 161 enrolled · United States, France, Switzerland
- Oct 18, 2021Phase 1 study in Hepatic InsufficiencyNCT05093972 · 22 planned
- Sep 27, 2024Phase 1 study in HealthyNCT06619678 · 36 enrolled · United States
- Mar 17, 2025Phase 2 study in Acquired Immunodeficiency SyndromeNCT06891066 · 150 enrolled · United States, Australia, Puerto Rico and more
- Dec 1, 2025Phase 3 study in Acquired Immunodeficiency SyndromePhase 3 reachedNCT07266831 · 570 planned · United States, Argentina, Canada and more
- Dec 12, 20252 phase 1 studies in HealthyNCT07305831, NCT07334886
- Apr 7, 2026Phase 1 study in HealthyNCT07530289 · 12 enrolled · United States
- May 12, 2026Phase 1 study in HealthyNCT07595263 · 14 enrolled · United States
Ahead
- Jun 29, 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT05093972
- Aug 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeNCT06891066
- Feb 1, 2029Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07266831
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07595263Healthy · United States | 1 | Completed | Sep 29, 2026 | 14 |
| NCT07530289Healthy · United States | 1 | Completed | May 23, 2026 | 12 |
| NCT07334886Healthy · United States | 1 | Completed | Nov 11, 2025 | 8 |
| NCT07305831Healthy · United States | 1 | Completed | Apr 9, 2026 | 62 |
| NCT07266831Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more | 3 | Recruiting | Feb 1, 2029 | 570 |
| NCT06891066Acquired Immunodeficiency Syndrome · United States, Australia, Puerto Rico and more | 2 | Active, not recruiting | Aug 10, 2027 | 150 |
| NCT06619678Healthy · United States | 1 | Completed | Jun 23, 2024 | 36 |
| NCT05093972Hepatic Insufficiency | 1 | Not yet recruiting | Jun 29, 2027 | 22 |
| NCT04564547HIV-1 Infection · United States, France, Switzerland | 2 | Completed | Jan 30, 2025 | 161 |
| NCT02174159HIV-1 Infection | 1 | Completed | Jul 16, 2015 | 18 |
How it is read
Names in the registry
- “Ulonivirine”, 6 entries
- “ULO”, 2 entries
- “MK-8507”, 1 entry
- “[14C]Ulonivirine”, 1 entry
Conditions, from the studies’ own filings
- Infections, 2 studies
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.